SERPINC1突变对先天性抗凝血酶缺乏症儿童血栓表型的影响——国际血栓与止血学会儿童抗凝血酶缺乏症数据库与生物样本库的首次分析
该前瞻性儿童数据库与DNA生物样本库在加拿大和美国4家三级中心试点入组43例先天性抗凝血酶缺乏症患儿,其中19例(44%)有静脉血栓栓塞史;完成SERPINC1测序的31例中检出21种独特突变。携带无义突变的患儿5年无VTE生存概率显著低于错义突变携带者(66.7% vs 92.0%,p=.0012)。
要点
- 43例患儿中19例(44%)有静脉血栓栓塞史,诊断时中位年龄12.8岁。
- 携带无义突变的患儿5年无VTE生存概率低于错义突变携带者,差异有统计学意义。
- 作者认为该研究首次记录儿童无义突变携带者的严重血栓表型,强调基因检测的重要性。
核心结论
- 作者认为这是首个记录SERPINC1无义突变携带者较错义突变携带者呈现严重血栓表型的儿童研究,强调基因检测的重要性。
研究设计与样本
- 2017年建立先天性抗凝血酶缺乏症前瞻性儿童数据库与DNA生物样本库,试点阶段在加拿大和美国4家三级中心开放。
- 各参与中心获研究伦理委员会批准,符合条件者的监护人/受试者签署书面知情同意/同意。
- 美国中心的DNA提取和SERPINC1测序集中进行。
- 采用标准统计方法总结参数,用Kaplan-Meier法评估无VTE生存概率。
主要发现
- 共入组43例参与者(25例女性),来自31个独特家系,入组时中位年龄14.8岁(范围1-21岁)。
- 中位抗凝血酶活性为52%(范围24%-87%),中位抗凝血酶抗原(n=20)为55%(范围38%-110%)。
- 19例(44%)参与者有静脉血栓栓塞史,VTE诊断时中位年龄12.8岁(范围0.1-19.2岁)。
- 31例参与者完成SERPINC1测序,鉴定出21种独特突变,包括5种新变异。
- 错义突变携带者5年无VTE生存概率为92.0%(95%CI:71.6%-97.9%),无义突变携带者为66.7%(95%CI:19.5%-90.4%),错义突变携带者较高,p=.0012。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The natural history and genotype-phenotype correlation of congenital antithrombin (AT) deficiency in children are unknown. OBJECTIVES: To describe the clinical presentation of congenital AT deficiency in children and evaluate its correlation to specific mutations in SERPINC1. METHODS: In 2017, a prospective pediatric database and DNA biorepository for congenital AT deficiency was established. During the pilot phase, the database was opened at 4 tertiary care centers in Canada and US. Approval from research ethics board was obtained at each participating center. Written consent/assent was obtained from guardians/subjects who met eligibility. Demographic/clinical data were uploaded into a database. DNA extraction and SERPINC1 sequencing were centralized for US centers. Standard statistical methods were used to summarize parameters. Probability of VTE-free survival was assessed using the Kaplan-Meier method. RESULTS: Overall, 43 participants (25 females) from 31 unique kindreds were enrolled. Median age (range) at enrollment was 14.8 years (1-21 years). Median AT activity was 52% (24%-87%), and median AT antigen (n = 20) was 55% (38%-110%). Nineteen (44%) participants had a history of venous thromboembolism (VTE). Median age at VTE diagnosis was 12.8 years (0.1-19.2 years). SERPINC1 sequencing was completed for 31 participants and 21 unique mutations were identified, including 5 novel variants. Probability of 5-year VTE-free survival (95% CI) for carriers of missense mutations (92.0% [95% CI: 71.6%-97.9%]) was significantly higher compared with carriers of null mutations (66.7% [95% CI: 19.5%-90.4%]); p = .0012. CONCLUSION: To our knowledge, this is the first pediatric study to document a severe thrombotic phenotype in carriers of null mutations in SERPINC1, when compared with carriers of missense mutations; underscoring the importance of genetic testing.
引用
- Kumar R, Bakeer N, Dawson J, et al. Impact of SERPINC1 mutation on thrombotic phenotype in children with congenital antithrombin deficiency-first analysis of the International Society on Thrombosis and Haemostasis pediatric antithrombin deficiency database and biorepository. J Thromb Haemost. 2023. PMID: 36764659. doi:10.1016/j.jtha.2023.01.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。